Great Debate: SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction

被引：2
作者：
Packer, Milton [1 ,2 ]
Cleland, John G. F. [3 ]
Bauersachs, Johann [4 ]
机构：
[1] Baylor Heart & Vasc Inst, Dallas, TX USA
[2] Imperial Coll, London, England
[3] Univ Glasgow, British Heart Fdn Ctr Res Excellence, Sch Cardiovasc & Metab Hlth, Glasgow, Scotland
[4] Hannover Med Sch, Dept Cardiol & Angiol, Carl Neuberg Str 1, D-30625 Hannover, Germany
来源：
EUROPEAN HEART JOURNAL | 2024年 / 45卷 / 25期
关键词：
Heart failure; SGLT2; inhibitor; Pharmacotherapy; Foundational drugs; Hospitalization; EMPAGLIFLOZIN; RISK; DAPAGLIFLOZIN; HYPERTENSION; METAANALYSIS; DIURETICS; MORTALITY; MEDICINE; BENEFITS; OUTCOMES;
D O I：
10.1093/eurheartj/ehae300
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Graphical Abstract SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction. ARNI, angiotensin receptor-neprilysin inhibitor; CV, cardiovascular; GRMT, guideline-recommended medical therapy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; MRA, mineralocorticoid receptor antagonist; SGLT2i, sodium-glucose cotransporter 2 inhibitor.
引用
收藏
页码：2186 / 2196
页数：11
相关论文
共 50 条
[31]   Empagliflozin and other SGLT2 inhibitors in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis [J].
Hamid, Abdulrahman Khaldoon ;
Tayem, AbdulJaber A'Ed ;
Al-Aish, Sandra Thair ;
Al Sakini, Ahmed Sermed ;
Hadi, Dalia Dhia ;
Al-Aish, Rami Thair .
THERAPEUTIC ADVANCES IN CARDIOVASCULAR DISEASE, 2024, 18
[32]   SGLT2 inhibitor therapy in patients with advanced heart failure and reduced ejection fraction [J].
Nuzzi, Vincenzo ;
Manca, Paolo ;
Parisi, Francesca ;
Madaudo, Cristina ;
Sciacca, Sergio ;
Cannizzo, Noemi ;
Mule, Massimiliano ;
Cipriani, Manlio G. .
CURRENT PROBLEMS IN CARDIOLOGY, 2024, 49 (11)
[33]   Atrial Fibrillation Ablation Should Be First-line Therapy in Patients with Heart Failure Reduced Ejection Fraction [J].
Agasthi, Pradyumna ;
Tseng, Andrew ;
Lee, Justin Z. ;
Mulpuru, Siva K. .
CARDIOLOGY CLINICS, 2019, 37 (02) :185-+
[34]   Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction [J].
Tomasoni, Daniela ;
Fonarow, Gregg C. ;
Adamo, Marianna ;
Anker, Stefan D. ;
Butler, Javed ;
Coats, Andrew J. S. ;
Filippatos, Gerasimos ;
Greene, Stephen J. ;
McDonagh, Theresa A. ;
Ponikowski, Piotr ;
Rosano, Giuseppe ;
Seferovic, Petar ;
Vaduganathan, Muthiah ;
Voors, Adriaan A. ;
Metra, Marco .
EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (03) :431-441
[35]   SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction A Paradigm Shift Toward Dual Cardio-Renal Protection [J].
Rastogi, Tripti ;
Girerd, Nicolas .
HEART FAILURE CLINICS, 2022, 18 (04) :561-577
[36]   SGLT2 INHIBITORS: RATIONALE AND PERSPECTIVES OF USE IN HEART FAILURE [J].
Kobalava, Zh. D. ;
Lazarev, P., V ;
Villevalde, S. V. .
KARDIOLOGIYA, 2018, 58 (02) :42-54
[37]   Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction [J].
Krittayaphong, Rungroj ;
Permsuwan, Unchalee .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021, 322 :183-190
[38]   Practical Guidance for the Use of SGLT2 Inhibitors in Heart Failure [J].
Cavallari, Ilaria ;
Crispino, Simone Pasquale ;
Segreti, Andrea ;
Ussia, Gian Paolo ;
Grigioni, Francesco .
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2023, 23 (06) :609-621
[39]   SGLT2 Inhibitors Should Be Considered for All Patients With Heart Failure [J].
Ahmad, Tariq ;
Desai, Nihar R. ;
Velazquez, Eric J. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 80 (14) :1311-1313
[40]   The Pleiotropic Effects of SGLT2 Inhibitors Remodeling the Treatment of Heart Failure [J].
Goldberg, Lee R. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (03) :256-258
12345